Traditional Chinese medicine and cancer: History, present situation, and development

Thoracic Cancer

Volumn 6, Issue 5, 2015, Pages 561-569

  Liu, Jie ^a   Wang, Shuo ^a,b   Zhang, Ying ^a   Fan, Hui Ting ^a   Lin, Hong Sheng ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Cancer; Development; History; Present situation; Traditional Chinese medicine

Indexed keywords

CAPSAICIN; CISPLATIN; INTERLEUKIN 12; MITOGEN ACTIVATED PROTEIN KINASE; NAVELBINE; OXYMATRINE; TRANSFORMING GROWTH FACTOR BETA;

ABDOMINAL SURGERY; ADVANCED CANCER; ANGIOGENESIS; ANOREXIA; APOPTOSIS; ASTRAGALUS (PLANT); BLEEDING; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER INHIBITION; CANCER PATIENT; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CAUSE OF DEATH; CD4+ CD25+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MATURATION; CELL MEDIATED CYTOTOXICITY; CHEMORADIOTHERAPY; CLINICAL RESEARCH; COLORECTAL CANCER; COUGHING; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; DYSPLASIA; DYSPNEA; EDEMA; ESOPHAGUS CANCER; EVIDENCE BASED MEDICINE; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GENE SEQUENCE; GINSENG; HAIR LOSS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEMOPTYSIS; HUMAN; IMMUNOREGULATION; INTESTINE METAPLASIA; KARNOFSKY PERFORMANCE STATUS; KIDNEY FAILURE; LEUKOPENIA; LIVER FAILURE; MASTECTOMY; META ANALYSIS (TOPIC); METASTASIS; MOUTH INJURY; MULTICENTER STUDY (TOPIC); NASOPHARYNX CARCINOMA; NAUSEA; NEOPLASM; NON SMALL CELL LUNG CANCER; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRECANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHIZOME; STANDARDIZATION; STOMACH CANCER; THORAX PAIN; TRADITIONAL MEDICINE; TREATMENT RESPONSE; TREND STUDY; TUMOR RECURRENCE; TUMOR VOLUME; ULCER; UPREGULATION; VOMITING;

EID: 84940961606     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/1759-7714.12270     Document Type: Review

References (80)

1. Wang B (Tang Dynasty). The Yellow Emperor's Inner Canon. Ancient Books of TCM Publishing House, Beijing 2003.
2. Hua T (Han Dynasty). The Central Treasury Canon. People's Medical Publishing House, Beijing 2007.
3. Li ZZ (Ming Dynasty). Indispensable Medical Reading. People's Medical Publishing House, Beijing 2006.
4. McCulloch M, See C, Shu XJ etal. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: Meta-analysis of randomized trials. J Clin Oncol 2006; 24: 419-430.
5. Gan T, Wu Z, Tian L, Wang Y. Chinese herbal medicines for induction of remission in advanced or late gastric cancer. Cochrane Database Syst Rev 2010; (1)CD005096.
6. Li SG, Chen HY, Ou-Yang CS etal. The efficacy of Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis. PLoS ONE 2013; 8 (2): e57604.
7. Zhong LL, Chen HY, Cho WC, Meng XM, Tong Y. The efficacy of Chinese herbal medicine as an adjunctive therapy for colorectal cancer: A systematic review and meta-analysis. Complement Ther Med 2012; 20: 240-252.
8. Mao CG, Tao ZZ, Wan LJ, Han JB, Chen Z, Xiao BK. The efficacy of traditional Chinese medicine as an adjunctive therapy in nasopharyngeal carcinoma: A systematic review and meta-analysis. J BUON 2014; 19: 540-548.
9. Zhang DZ, Xu JD. [Clinical and experimental researches on improving radiation sensibility for lung cancer patients.] Chin J Surg Integr Tradit West Med 1998; 4: 71-75. (In Chinese.)
10. Zhou DH, Lin LZ, Zhou YQ. [Effect of Chinese herbal medicine in prolonging median survival time in patients with non-small-cell lung cancer.] J Guangzhou Univ Tradit Chin Med 2005; 7: 255-258. (In Chinese.)
11. Xu ZY, Jin CJ, Zhou CC etal. Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy. J Cancer Res Clin Oncol 2011; 137: 1117-1122.
12. Liu JX, Shi ZM, Xu ZY. [Studies on late primary adenocarcinoma of lung treated by methods of nourishing yin to replenish fluid and warming Yang to benefit Qi.] J Tradit Chin Med 1995; 36: 155-158. (In Chinese.)
13. Piao BK, Tang WX, Zhang ZQ, Lin HS, Duan FW, Yu GQ. [The clinical observation of Feiliuping paste curing advanced lung cancer-and clinical analysis of 339 cases.] J Tradit Chin Med 1991; 4: 21-23. (In Chinese.)
14. Tang WX, Zhang ZQ, Lin HS, Hou W, Piao BK. [The clinical observation of the TCM treatment of NSCLC.] J Tradit Chin Med 1994; 5: 283-285. (In Chinese.)
15. Sun Y, Lin HS, Zhu YZ etal. [A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine+cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients.] Chin J Lung Cancer 2006; 9: 254-258. (In Chinese.)
16. Lin HS, Zhang Y. [Evidence-based medical study of TCM on non small cell lung cancer.] World Sci Technol 2008; 10: 121-125. (In Chinese.)
17. Xu W, Yang G, Xu Y etal. The possibility of traditional Chinese medicine as maintenance therapy for advanced nonsmall cell lung cancer. Evid Based Complement Alternat Med 2014; 2014: 278917.
18. Xu L, Liu JX. [Effect of yifei kangliu yin on lung cancer metastasis and immune function.] Chin J Integr Med 1997; 17: 401-403. (In Chinese.)
19. Sun GZ, Yu GQ, Zhang PT. [Clinical and mechanism research on Fu Zheng Pei Ben serial formulas' application on gastric cancer treatment.] J Zhejiang Univ Tradit Chin Med 2005; 33: 695-700. (In Chinese.)
20. Wang W, Xu L, Shen C. Effects of traditional Chinese medicine in treatment of breast cancer patients after mastectomy: A meta-analysis. Cell Biochem Biophys 2014. doi: 10.1007/s12013-014-0348-z
21. Chen ZF, Zhang JH. [Meta research of TCM treatment for precancerous lesions of esophageal cancer.] Traditi Chin Med Res 1999; 12: 20-21. (In Chinese.)
22. Miu CR, Shen H. [Meta-analysis of effectiveness of Chinese medicinal herbs in treating precancerous lesions of gastric cancer.] J Liaoning Univ Tradit Chin Med 2009; 11: 35-37. (In Chinese.)
23. Lin Y, Fu J. [Effect of Fei'an decoction on the symptomatic relief in postoperative pulmonary carcinoma.] J Guangzhou Univ Tradit Chin Med 1998; 02: 21-23. (In Chinese.)
24. Me H, Chen ZC. The effect of shenfu injection on human immune function at lung cancer patients. Guizhou Med J 2003; 27: 796.
25. He Y. [Objective to Tanreqing Injection for Sputum Retention after lung cancer operation.] J Emerg Tradit Chin Med 2009; 2: 194. (In Chinese.)
26. Luo XB, Li L, Liu NM. [Effect observation of TCM treatment for breast cancer patients after operation.] J Emerg Tradit Chin Med 2008; 17: 770-771. (In Chinese.)
27. Zuo MH, Li QW, Sun T. [76 malignancy intestinal obstruction cases of clinical observation by enema with Chinese medicine.] China J Tradit Chin Med Pharm 2007; 22: 654-655. (In Chinese.)
28. He HB, Wang F. [The idea and method of treatment of Bile Reflex Gastritis with Zheng-dan decoction.] Med Philos 1995; 16: 599-600. (In Chinese.)
29. Saif MW, Li J, Lamb L etal. First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 2014; 73: 373-380.
30. Aoyama T, Nishikawa K, Takiguchi N etal. Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastriccancer chemotherapy-induced oral mucositis. Cancer Chemother Pharmacol 2014; 73: 1047-1054.
31. Chinese Academy of Medical Sciences (CAMS) TCM Guidelines of Evidence-based Clinical Practice - Internal Medicine of TCM. China Press of Traditional Chinese Medicine, Beijing 2010.
32. Lin HS. Guidelines of Diagnosis and Therapy in Oncology with Traditional Chinese Medicine. People's Health Publishing House, Beijing 2014.
33. Wang YH, Xu AL. Zheng: A systems biology approach to diagnosis and treatments. Science 2014; 346 (6216 Suppl.): s13-s15.
34. Yao K, Ma Y, Ma W etal. Shenqifuzheng injection combined with chemotherapy in the treatment of advanced gastric cancer: A systematic review and meta-analysis. J Cancer Res Ther 2014; 10 (Suppl. 1): 70-74.
35. Zhao Z, Fan H, Higgins T etal. Fufang Kushen injection inhibits sarcoma growth and tumor-induced hyperalgesia via TRPV1 signaling pathways. Cancer Lett 2014; 355: 232-241.
36. Fan CX, Lin CL, Liang L etal. [Enhancing effect of compound Kusheng injection in combination with chemotherapy for patients with advanced non-small cell lung cancer.] Chin J Oncol 2010; 32: 294-297. (In Chinese.)
37. Liu S, Wang H, Lin H. [The clinical research of Kangai injection with chemotherapy in the treatment of advanced non-small cell lung cancer.] World Chin Med 2014; 03: 323-325. (In Chinese.)
38. Hu B, An HM, Shen KP. [Documents research of TCM cancer treatment of SCI journals.] Chin J Ethnomedicine Ethnopharmacy 2009; 20: 26-27. (In Chinese.)
39. Dong Y, Lu B, Zhang X etal. Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway. Carcinogenesis 2010; 31: 2097-2104.
40. Tsai CH, Lin FM, Yang YC etal. Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice. Clin Cancer Res 2009; 15: 5435-5444.
41. Yue GG, Chan BC, Kwok HF etal. Anti-angiogenesis and immunomodulatory activities of an anti-tumor sesquiterpene bigelovin isolated from Inula helianthus-aquatica. Eur J Med Chem 2013; 59: 243-252.
42. Yeh JC, Cindrova-Davies T, Belleri M etal. The natural compound n-butylidenephthalide derived from the volatile oil of Radix Angelica sinensis inhibits angiogenesis in vitro and in vivo. Angiogenesis 2011; 14: 187-197.
43. Zhang XW, Yan XJ, Zhou ZR etal. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010; 328: 240-243.
44. Zhang H, Su X, Guo L etal. Silencing SATB1 inhibits the malignant phenotype and increaes sensitivity of human osteosarcoma U2OS cells to arsenic trioxide. Int J Med Sci 2014; 11: 1262-1269.
45. Liu SS, Wang XP, Li XB etal. Zoledronic acid exerts antitumor effects in NB4 acute promyelocytic leukemia cells by inducing apoptosis and S phase arrest. Biomed Pharmacother 2014; 68: 1031-1036.
46. Luo KW, Ko CH, Yue GG etal. Green tea (Camellia sinensis) extract inhibits both the metastasis and osteolytic components of mammary cancer 4T1 lesions in mice. J Nutr Biochem 2014; 25: 395-403.
47. Li PC, Lam E, Roos WP, Zdzienicka MZ, Kaina B, Efferth T. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res 2008; 68: 4347-4351.
48. Zhang L, Wu C, Zhang Y etal. Comparison of efficacy and toxicity of traditional Chinese medicine (TCM) herbal mixture LQ and conventional chemotherapy on lung cancer metastasis and survival in mouse models. PLoS ONE 2014; 9 (10): e109814.
49. Prasad S, Gupta SC, Tyagi AK, Aggarwal BB. Curcumin, a component of golden spice: From bedside to bench and back. Biotechnol Adv 2014; 32: 1053-1064.
50. Li L, Yue GG, Pu JX etal. Eriocalyxin B-induced apoptosis in pancreatic adenocarcinoma cells through thiol-containing antioxidant systems and downstream signalling pathways. Curr Mol Med 2014; 14: 673-689.
51. Tang PM, Zhang DM, Xuan NH etal. Photodynamic therapy inhibits P-glycoprotein mediated multidrug resistance via JNK activation in human hepatocellular carcinoma using the photosensitizer pheophorbide a. Mol Cancer 2009; 8: 56.
52. Chen X, Murakami T, Oppenhei JJ, Howard OM. Triptolide, a constituent of immunosuppressive Chinese herbal medicine, is a potent suppressor of dendritic-cell maturation and trafficking. Blood 2005; 106: 2409-2416.
53. Cho WC, Leung KN. In vitro and in vivo anti-tumor effects of Astragalus membranaceus. Cancer Lett 2007; 252: 43-54.
54. Ragupathi G, Yeung KS, Leung PC etal. Evaluation of widely consumed botanicals as immunological adjuvants. Vaccine 2008; 26: 4860-4865.
55. Yue GG, Chan BC, Han XQ etal. Immunomodulatory activities of Ganoderma sinense polysaccharides in human immune cells. Nutr Cancer 2013; 65: 765-774.
56. Zhang QY, Mao JH, Liu P etal. A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A 2009; 106: 3378-3383.
57. Zhao J, Jiang P, Zhang W. Molecular networks for the study of TCM pharmacology. Brief Bioinform 2010; 11: 417-430.
58. Lam W, Bussom S, Guan F etal. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med 2010; 2 (45): 45ra59.
59. Guo B, Zhang T, Su J, Wang K, Li X. Oxymatrine targets EGFR(p-Tyr845) and inhibits EGFR-related signaling pathways to suppress the proliferation and invasion of gastric cancer cells. Cancer Chemother Pharmacol 2015; 75: 353-363.
60. Xu W, Lin H, Zhang Y. Compound Kushen Injection suppresses human breast cancer stem-like cells by down-regulating the canonical Wnt/β-catenin pathway. J Exp Clin Cancer Res 2011; 30: 103.
61. Zhang Y, Piao B, Zhang Y. Oxymatrine diminishes the side population and inhibits the expression of β-catenin in MCF-7 breast cancer cells. Med Oncol 2011; 28 (Suppl. 1): S99-107.
62. Zheng HG, Piao BK, Lin HS. [Molecular mechanism of Fei Liu Ping ointment and its modified formulas regulating antigen presentation function of DC.] Chin Arch Tradit Chin Med 2007; 25: 1133-1136. (In Chinese.)
63. Fan HT, Lin HS, Li J, Qi X, Pei YX, Wu H. Effect of cultured cordyceps militaris on CD4+CD25+ regulatory T cells in Lewis lung carcinoma bearing mice. Chin J Cancer Prev Treat 2009; 15: 1130-1134. (In Chinese.)
64. Zhao Z, Fan H, Higgins T etal. Fufang Kushen injection inhibits sarcoma growth and tumor-induced hyperalgesia via TRPV1 signaling pathways. Cancer Lett 2014; 355: 232-241.
65. Xu D, Lao Y, Xu N etal. Identification and characterization of anticancer compounds targeting apoptosis and autophagy from Chinese native Garcinia species. Planta Med 2015; 81: 79-89.
66. Brandl MB, Pasquier E, Li F etal. Computational analysis of image-based drug profiling predicts synergistic drug combinations: Applications in triple-negative breast cancer. Mol Oncol 2014; 8: 1548-1560.
67. Yang C, Liu HW, Wang LC. [Study on the differential gene expressions of chronic hepatitis B patients of gan depression Pi deficiency syndrome and Pi-Wei damp-hear syndrome.] Chin J Integr Med 2012; 08: 1032-1037. (In Chinese.)
68. Xie LH, Zhao YP, Chen K, Lai YL, Ge JR. [Bioinformatics analysis of genes expression profiles of postmenopausal osteoporosis with Kidney Yin deficiency.] Journal of Clinical Rehabilitative Tissue Engineering Research 2011; 15: 2833-2837. (In Chinese.)
69. Li J, Li L, Liu R, Lin HS. Establishing Chinese medicine characteristic tumor response evaluation system is the key to promote internationalization of Chinese medicine oncology. Chin J Integr Med 2012; 18: 730-736.
70. Hou W, Liu J, Shi WG, Lin HS. [Multi-center, randomized, controlled clinical study of radiation pneumonitis treated with compound matrine injection in primary lung cancer patients.] Chin J New Drugs 2013; 17: 2065-2068. (In Chinese.)
71. Lin HS, Yang ZY, Zhang PT etal. [Clinical efficacy observation of Shengxue Pills in treating hematology decline caused by chemotherapy in nonsmall-cell lung cancer.] China J Tradit Chin Med Pharm 2013; 08: 2491-2494. (In Chinese.)
72. Lin HS, Sun GP, Qing FZ etal. A randomized, double-blinded, drug-controlled and multicentre clinical trial of chemotherapy assisted with Jinlong capsule on gastric cancer. Cancer Res Prev Treat 2013; 1: 12-15.
73. Leung ELH, Wong VKW, Jiang ZH, Li T, Liu L. Integrated network-based medicine: The role of traditional Chinese medicine in developing a new generation of medicine. Science 2014; 346 (6216 Suppl.): s16-18.
74. Tian HQ, Wang YJ, Wang B etal. [Effect of ruji recipe on the post-surgical survival of female breast cancer patients.] Chin J Integr Med 2013; 33: 1336-1340. (In Chinese.)
75. Yang XB, Wu WY, Long SQ, Deng H, Pan ZQ. Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lungcancer: A retrospective case-control study. Complement Ther Med 2014; 22: 1010-1018.
76. You YL. [TCM cut into the targeted therapy of lung cancer.] Liaoning J Tradit Chin Med 2006; 10: 1227-1229. (In Chinese.)
77. Johnston MF, Hays RD, Subramanian SK etal. Patient education integrated with acupuncture for relief of cancer-related fatigue randomized controlled feasibility study. BMC Complement Altern Med 2011; 11: 49.
78. Wesa K, Gubili J, Cassileth B. Integrative oncology: Complementary therapies for cancer survivors. Hematol Oncol Clin North Am 2008; 22: 343-353.
79. Running A, Seright T. Integrative oncology: Managing cancer pain with complementary and alternative therapies. Curr Pain Headache Rep 2012; 16: 325-331.
80. Piao BK, Wang YX, Xie GR etal. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients: A prospective randomized controlled clinical trial. Anticancer Res 2004; 24: 303-309.